Intellia Therapeutics Inc. (NTLA)
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NTLA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.40B
- EPS (TTM)
- -$3.35
- Dividend yield
- None
- 52-week range
- 8.09 – 18.48
- Day range
- 9.30 – 10.40
- Volume / Avg
- 15.18M / 5.03M
- Beta
- —
- Shares outstanding
- 140.36M
52-week range
NTLA stock today
On Nov 20, NTLA ended the session at $10.00, adding $0.48 (5.04%), versus the S&P 500's 3.70% decline. Volume was 3.0x the average at 15.18M shares, a sign of unusually heavy trading. Shares are 45.9% below their 52-week high of $18.48, set on Jul 2, 2026 and 23.7% above the 52-week low of $8.09, near the bottom of the past year's range.
NTLA is up 11.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.8%. Intellia Therapeutics has posted a net loss over the last twelve months (EPS of -$3.35), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Intellia Therapeutics
Company profileIntellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Dr. John M. Leonard M.D.
- Headquarters
- Cambridge, MA
- Employees
- 377
- IPO year
- 2016
- Website
- intelliatx.com
Financial highlights
Full financialsIn fiscal 2025, Intellia Therapeutics generated $67.7 million in revenue, up 16.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Intellia Therapeutics reported a net loss of $412.7 million, compared with a loss of $519.0 million a year earlier. Operating margin was -651.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $67.67M | $57.88M | $36.27M | $52.12M | $33.05M |
| Growth | +16.92% | +59.55% | -30.40% | +57.69% | -43.01% |
| Net income | $-412.69M | $-519.02M | $-481.19M | $-474.19M | $-267.89M |
| EPS (diluted) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
Analyst forecast
ForecastConsensus (20 analysts)
buy
Avg. price target
$22.78+127.80%
- Strong buy 1
- Buy 9
- Hold 6
- Sell 2
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.91 vs $-0.82
- Surprise
- -10.98%
NTLA news
All NTLA news- Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026GlobeNewswire
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in FocusNasdaqNTLA, REGN, TGTX, AMRX
- Intellia Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Business UpdatesNasdaqNTLA, MOG.B
- Intellia Therapeutics GAAP EPS of -$0.91 misses by $0.11, revenue of $7.16M misses by $2.61MSeeking Alpha
- Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswire
- Exelixis (EXEL) Surpasses Q3 Earnings and Revenue EstimatesNasdaqEXEL, NTLA
- Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026GlobeNewswire
Intellia Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CLDXCelldex Therapeutics Inc. | 27.42 | -1.93% | $2.15B | vs NTLA |
| QUITAchieve Life Sciences Inc. | 5.56 | -5.28% | $573.25M | vs NTLA |
| QDELQuidelOrtho Corporation | 8.32 | -6.73% | $570.86M | vs NTLA |
| MYGNMyriad Genetics Inc. | 5.46 | -1.44% | $523.74M | vs NTLA |
| NEOGNeogen Corporation | 10.55 | -2.77% | $2.30B | vs NTLA |
| TKNOAlpha Teknova Inc. | 7.63 | -2.30% | $479.95M | vs NTLA |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs NTLA |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs NTLA |
Indexes, lists and sector
Intellia Therapeutics stock FAQ
What is Intellia Therapeutics's stock price today?
NTLA last traded at $10.00 as of Nov 20, 4:00 PM EST, up 5.04% on the day. Prices are delayed at least 15 minutes.
Who is Intellia Therapeutics's CEO?
Dr. John M. Leonard M.D. is the chief executive officer of Intellia Therapeutics Inc., which has about 377 employees.
What is the NTLA 52-week high?
The 52-week high for NTLA is $18.48 and the 52-week low is $8.09. The stock is currently 45.9% below its high.